Atrial Fibrillation - Pipeline Review, H1 2017

Published: Mar, 2017 | Pages: 89 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Atrial Fibrillation - Pipeline Review, H1 2017, provides an overview of the Atrial Fibrillation (Cardiovascular) pipeline landscape.

Atrial fibrillation is an irregular and often rapid heart rate that commonly causes poor blood flow to the body. Symptoms include decreased blood pressure, weakness, lightheadedness, confusion and chest pain. The predisposing factors include age, heart disease, high blood pressure, family history and drinking alcohol. Treatments for atrial fibrillation may include medications and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Atrial Fibrillation - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Atrial Fibrillation (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Atrial Fibrillation (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Atrial Fibrillation and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 2, 2, 7 and 2 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 1 and 2 molecules, respectively.

Atrial Fibrillation (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Atrial Fibrillation (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Atrial Fibrillation (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Atrial Fibrillation (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Atrial Fibrillation (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Atrial Fibrillation (Cardiovascular)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Atrial Fibrillation (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Atrial Fibrillation (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Atrial Fibrillation - Overview
Atrial Fibrillation - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Atrial Fibrillation - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Atrial Fibrillation - Companies Involved in Therapeutics Development
Acesion Pharma Aps
Allosteros Therapeutics Inc
ARCA biopharma Inc
Armetheon Inc
AstraZeneca Plc
Bristol-Myers Squibb Company
Cardiome Pharma Corp
Daiichi Sankyo Company Ltd
Dong-A Socio Holdings Co Ltd
Gilead Sciences Inc
InCarda Therapeutics Inc
Merck & Co Inc
Nissan Chemical Industries Ltd
Nyken BV
OMEICOS Therapeutics GmbH
Verseon Corp
Atrial Fibrillation - Drug Profiles
AFC-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-919373 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bucindolol hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
budiodarone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
edoxaban tosylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
flecainide acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for Atrial Fibrillation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GS-967 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MK-1832 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NIP-151 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NYK-1112 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OMT-28 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Atrial Fibrillation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Block Calcium-Activated Potassium Channel for Atrial Fibrillation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Block Kv1.5 for Atrial Fibrillation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Block GIRK for Atrial Fibrillation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CaMKII for Arrhythmias and Heart Failure - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Thrombin for Cardiovascular Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
STP-023725 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vernakalant hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Atrial Fibrillation - Dormant Projects
Atrial Fibrillation - Discontinued Products
Atrial Fibrillation - Product Development Milestones
Featured News & Press Releases
Feb 23, 2017: Daiichi Sankyo Europe Receives CHMP Positive Opinion for Roteas (edoxaban)
Feb 13, 2017: Armetheon announces issuance of a new U.S. patent for its Phase 2 clinical stage novel oral anti-arrhythmic budiodarone
Dec 08, 2016: Daiichi Sankyo Announces Initiation of Real-World Study in LIXIANA (edoxaban) Patients Undergoing Diagnostic and Therapeutic Procedures in NVAF and VTE
Nov 09, 2016: Once-Daily Anticoagulant LIXIANA (edoxaban) Approved in Canada for Stroke Prevention in Atrial Fibrillation and for the Treatment and Prevention of Recurrent Deep-Vein Thrombosis and Pulmonary Embolism
Nov 07, 2016: Daiichi Sankyo Announces New Subgroup Analyses of Once-Daily SAVAYSA (edoxaban) in Patients with Non-Valvular Atrial Fibrillation to be Presented at AHA Scientific Sessions 2016
Oct 03, 2016: Daiichi Sankyo Announces Large-Scale Registry of Nonvalvular Atrial Fibrillation in the Elderly
Aug 30, 2016: ENSURE-AF Data Support the Efficacy and Safety Profile of Daiichi Sankyo's Once-Daily LIXIANA in Patients with Atrial Fibrillation Undergoing Cardioversion
Aug 30, 2016: Trial results for anticoagulants for cardioversion in AF patients published
Aug 24, 2016: Daiichi Sankyo Initiates ELDERCARE-AF Study of Anticoagulant Edoxaban
Aug 24, 2016: Data from Phase 3b ENSURE-AF Study Investigating Once-Daily SAVAYSA (edoxaban) in Patients with Atrial Fibrillation Undergoing Cardioversion Among 13 Daiichi Sankyo Clinical Presentations at ESC Congress 2016
May 11, 2016: Cardiome Announces Publication of Spanish Emergency Department BRINAVESS Study
May 02, 2016: New drug more effective in treating atrial fibrillation
Mar 31, 2016: Cardiome Announces Publication of Independent Study Comparing BRINAVESS to IBUTILIDE in Patients with Recent-Onset Atrial Fibrillation
Mar 24, 2016: Daiichi Sankyo to Present Findings From New Subgroup Analyses of Once-Daily SAVAYSA(edoxaban) in NVAF and VTE at ACC's 65th Annual Scientific Session
Jan 27, 2016: Cardiome Announces Filing of Orphan Drug Application for Oral Vernakalant with U.S. FDA
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables

Number of Products under Development for Atrial Fibrillation, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Atrial Fibrillation - Pipeline by Acesion Pharma Aps, H1 2017
Atrial Fibrillation - Pipeline by Allosteros Therapeutics Inc, H1 2017
Atrial Fibrillation - Pipeline by ARCA biopharma Inc, H1 2017
Atrial Fibrillation - Pipeline by Armetheon Inc, H1 2017
Atrial Fibrillation - Pipeline by AstraZeneca Plc, H1 2017
Atrial Fibrillation - Pipeline by Bristol-Myers Squibb Company, H1 2017
Atrial Fibrillation - Pipeline by Cardiome Pharma Corp, H1 2017
Atrial Fibrillation - Pipeline by Daiichi Sankyo Company Ltd, H1 2017
Atrial Fibrillation - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2017
Atrial Fibrillation - Pipeline by Gilead Sciences Inc, H1 2017
Atrial Fibrillation - Pipeline by InCarda Therapeutics Inc, H1 2017
Atrial Fibrillation - Pipeline by Merck & Co Inc, H1 2017
Atrial Fibrillation - Pipeline by Nissan Chemical Industries Ltd, H1 2017
Atrial Fibrillation - Pipeline by Nyken BV, H1 2017
Atrial Fibrillation - Pipeline by OMEICOS Therapeutics GmbH, H1 2017
Atrial Fibrillation - Pipeline by Verseon Corp, H1 2017
Atrial Fibrillation - Dormant Projects, H1 2017
Atrial Fibrillation - Dormant Projects, H1 2017 (Contd..1), H1 2017
Atrial Fibrillation - Dormant Projects, H1 2017 (Contd..2), H1 2017
Atrial Fibrillation - Discontinued Products, H1 2017
Atrial Fibrillation - Discontinued Products, H1 2017 (Contd..1), H1 2017